For example, in the 2019 Food and Drug Administration review of quizartinib for the treatment of adult patients with relapsed or refractory FLT3-internal tandem duplication–positive acute myeloid leukemia, early excess censoring (>10%) observed in the placebo group was noted and the drug was not approved then, in part because of concerns that the imbalanced censoring contributed to the OS advantage.16 The gene discussed is FLT3; the disease is acute myeloid leukemia.